123 related articles for article (PubMed ID: 16697762)
21. Adalimumab in rheumatoid arthritis.
Moreland L
Curr Rheumatol Rep; 2004 Oct; 6(5):333-4. PubMed ID: 15355743
[No Abstract] [Full Text] [Related]
22. Acute leukemia after infliximab therapy.
Alcaín G; Andrade RJ; Queipo de Llano MP; Moreno MJ; García-Cortés M; Franquelo E
Am J Gastroenterol; 2003 Nov; 98(11):2577. PubMed ID: 14638375
[No Abstract] [Full Text] [Related]
23. Switch to adalimumab in patients with Crohn's disease controlled by maintenance infliximab: prospective randomised SWITCH trial.
Van Assche G; Vermeire S; Ballet V; Gabriels F; Noman M; D'Haens G; Claessens C; Humblet E; Vande Casteele N; Gils A; Rutgeerts P
Gut; 2012 Feb; 61(2):229-34. PubMed ID: 21948942
[TBL] [Abstract][Full Text] [Related]
24. Maintenance of remission among patients with Crohn's disease on antimetabolite therapy after infliximab therapy is stopped.
Louis E; Mary JY; Vernier-Massouille G; Grimaud JC; Bouhnik Y; Laharie D; Dupas JL; Pillant H; Picon L; Veyrac M; Flamant M; Savoye G; Jian R; Devos M; Porcher R; Paintaud G; Piver E; Colombel JF; Lemann M;
Gastroenterology; 2012 Jan; 142(1):63-70.e5; quiz e31. PubMed ID: 21945953
[TBL] [Abstract][Full Text] [Related]
25. [Adalimumab for the treatment of Crohn's disease - consensus paper of the Working Group "chronic inflammatory bowel diseases" of the Austrian Society for Gastroenterology and Hepatology].
Reinisch W; Haas T; Kaser A; Petritsch W; Vogelsang H; Feichtenschlager T; Novacek G; Siebert F; Tilg H; Knoflach P
Z Gastroenterol; 2009 Apr; 47(4):372-80. PubMed ID: 19358065
[TBL] [Abstract][Full Text] [Related]
26. Effectiveness and safety of local adalimumab injection in patients with fistulizing perianal Crohn's disease: a pilot study.
Tonelli F; Giudici F; Asteria CR
Dis Colon Rectum; 2012 Aug; 55(8):870-5. PubMed ID: 22810472
[TBL] [Abstract][Full Text] [Related]
27. The impact of infliximab induction therapy on mucosal healing and clinical remission in Polish pediatric patients with moderate-to-severe Crohn's disease.
Kierkus J; Dadalski M; Szymanska E; Oracz G; Wegner A; Gorczewska M; Szymanska S; Woynarowski M; Ryzko J
Eur J Gastroenterol Hepatol; 2012 May; 24(5):495-500. PubMed ID: 22387887
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and safety of short-term adalimumab treatment in patients with active Crohn's disease who lost response or showed intolerance to infliximab: a prospective, open-label, multicentre trial.
Hinojosa J; Gomollón F; García S; Bastida G; Cabriada JL; Saro C; Ceballos D; Peñate M; Gassull MA;
Aliment Pharmacol Ther; 2007 Feb; 25(4):409-18. PubMed ID: 17269996
[TBL] [Abstract][Full Text] [Related]
29. Low serum trough levels are associated with post-surgical recurrence in Crohn's disease patients undergoing prophylaxis with adalimumab.
Bodini G; Savarino V; Peyrin-Biroulet L; de Cassan C; Dulbecco P; Baldissarro I; Fazio V; Giambruno E; Savarino E
Dig Liver Dis; 2014 Nov; 46(11):1043-6. PubMed ID: 25169962
[TBL] [Abstract][Full Text] [Related]
30. A practical, evidence-based guide to the use of adalimumab in Crohn's disease.
Rubin DT; Panaccione R; Chao J; Robinson AM
Curr Med Res Opin; 2011 Sep; 27(9):1803-13. PubMed ID: 21809894
[TBL] [Abstract][Full Text] [Related]
31. Clinical experience with adalimumab in a multicenter Swiss cohort of patients with Crohn's disease.
Nichita C; Stelle M; Vavricka S; El-Wafa Ali A; Ballabeni P; de Saussure P; Straumann A; Rogler G; Michetti P
Digestion; 2010; 81(2):78-85. PubMed ID: 20093835
[TBL] [Abstract][Full Text] [Related]
32. Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn's disease.
Karmiris K; Paintaud G; Noman M; Magdelaine-Beuzelin C; Ferrante M; Degenne D; Claes K; Coopman T; Van Schuerbeek N; Van Assche G; Vermeire S; Rutgeerts P
Gastroenterology; 2009 Nov; 137(5):1628-40. PubMed ID: 19664627
[TBL] [Abstract][Full Text] [Related]
33. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial.
Hanauer SB; Sandborn WJ; Rutgeerts P; Fedorak RN; Lukas M; MacIntosh D; Panaccione R; Wolf D; Pollack P
Gastroenterology; 2006 Feb; 130(2):323-33; quiz 591. PubMed ID: 16472588
[TBL] [Abstract][Full Text] [Related]
34. Mucosal healing in Crohn's disease: what you see is what you get?
Mahadevan U
Gastrointest Endosc; 2006 Mar; 63(3):443-4. PubMed ID: 16500393
[No Abstract] [Full Text] [Related]
35. Severe cutaneous psoriasis after certolizumab pegol treatment: report of a case.
Mocciaro F; Renna S; Orlando A; Cottone M
Am J Gastroenterol; 2009 Nov; 104(11):2867-8. PubMed ID: 19888257
[No Abstract] [Full Text] [Related]
36. Retrospective Evaluation of the Safety and Effect of Adalimumab Therapy (RESEAT) in pediatric Crohn's disease.
Rosh JR; Lerer T; Markowitz J; Goli SR; Mamula P; Noe JD; Pfefferkorn MD; Kelleher KT; Griffiths AM; Kugathasan S; Keljo D; Oliva-Hemker M; Crandall W; Carvalho RS; Mack DR; Hyams JS
Am J Gastroenterol; 2009 Dec; 104(12):3042-9. PubMed ID: 19724267
[TBL] [Abstract][Full Text] [Related]
37. Timing infliximab therapy in pediatric Crohn's disease.
Kirschner BS; Huo D
Gastroenterology; 2007 Mar; 132(3):1167-70. PubMed ID: 17383435
[No Abstract] [Full Text] [Related]
38. Early clinical remission and normalisation of CRP are the strongest predictors of efficacy, mucosal healing and dose escalation during the first year of adalimumab therapy in Crohn's disease.
Kiss LS; Szamosi T; Molnar T; Miheller P; Lakatos L; Vincze A; Palatka K; Barta Z; Gasztonyi B; Salamon A; Horvath G; Tóth GT; Farkas K; Banai J; Tulassay Z; Nagy F; Szenes M; Veres G; Lovasz BD; Vegh Z; Golovics PA; Szathmari M; Papp M; Lakatos PL;
Aliment Pharmacol Ther; 2011 Oct; 34(8):911-22. PubMed ID: 21883326
[TBL] [Abstract][Full Text] [Related]
39. Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial.
Targan SR; Feagan BG; Fedorak RN; Lashner BA; Panaccione R; Present DH; Spehlmann ME; Rutgeerts PJ; Tulassay Z; Volfova M; Wolf DC; Hernandez C; Bornstein J; Sandborn WJ;
Gastroenterology; 2007 May; 132(5):1672-83. PubMed ID: 17484865
[TBL] [Abstract][Full Text] [Related]
40. Efficacy and safety of adalimumab in Crohn's disease: meta-analysis of placebo-controlled trials.
Huang ML; Ran ZH; Shen J; Li XB; Xu XT; Xiao SD
J Dig Dis; 2011 Jun; 12(3):165-72. PubMed ID: 21615869
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]